CRO Vendor Consolidation: How Mid-Size CROs and CDMOs Stay on the Sponsor Shortlist
Author: Imen Jelassi, Founder, Corstrate, Life Sciences Business Development Consultant
Key Takeaways
Consolidation is now the default procurement posture. Sponsors are reducing vendor counts by roughly 20 to 40% and moving toward enterprise-wide partnerships with fewer, more capable suppliers (Beroe, a procurement intelligence firm).
Procurement now scores outcomes, not rate cards. Beroe advises buyers to tie commercial terms to cycle times, enrollment, deviations and data quality, and to "prioritize productivity over price cuts". Vendors that cannot show these numbers cannot defend their seat.
Fewer vendors does not mean one vendor. Research on CDMO networks finds no evidence-based ideal number of partners, and treats consolidation as network design rather than vendor reduction (Pharma's Almanac). Specialist seats survive when they are clearly justified.
Three moves protect a seat: specialize, partner, prove platform value. Each answers a different procurement question, and a mid-size CRO or CDMO usually needs two of the three, not all of them.
Defense is a BD job, not only an operations job. The vendors that stay on the shortlist run account reviews, share their own KPI data before it is asked for, and build relationships with both procurement and the scientific sponsor well before a category review.
What CRO vendor consolidation by sponsors actually means
Vendor consolidation is the sponsor-side effort to replace a long, fragmented supplier list with a short one. Instead of running an RFP for every study or batch, a sponsor pre-selects a handful of partners per category, negotiates once and routes work to them. Beroe, a procurement intelligence firm, reports that organizations are reducing vendor counts by roughly 20 to 40%, shifting toward "fewer, more capable partners" with end-to-end visibility across data, operations and clinical supply (Beroe).
The supply side is consolidating too. Large CROs are buying niche specialists in rare disease, biomarkers, radiopharma and analytics, and the planned acquisition of the eClinical platform Clario by Thermo Fisher, reported at about 9.4 billion US dollars, is cited as evidence that clinical services and digital platforms are converging (Beroe). Clinical development services are expected to represent roughly 65 to 70% of outsourced pharma R&D spending in 2026, so the money at stake in these decisions is large.
If you have searched for "cro vendor consolidation sponsors", you are probably asking one of two questions: how do I get on the shortlist, or how do I stay on it. The first is covered in our guide to getting on a pharma preferred vendor list. This article is about the second, which is a different problem with different tools.
Applied Clinical Trials makes the underlying shift explicit: a transactional, fee-for-service approach is "insufficient for modern drug development", and strategic partnerships are defined by "a high level of business intimacy, shared governance, and mutual accountability" (Applied Clinical Trials). A vendor that still behaves transactionally is easy to consolidate away.
What procurement measures once you are already on the list
Once a vendor has a seat, procurement stops asking whether it is qualified and starts asking whether it is worth keeping. Beroe's 2026 guidance describes the scorecard in unusually concrete terms:
Contract KPIs: enrollment velocity, screen-failure rate, query-closure time, site-activation cycle time, temperature-excursion rates and CTIS RFI turnaround time.
Partnership KPIs: cycle times, recruitment performance, quality and RBQM indices, decentralized trial adoption and diversity metrics.
Performance-linked payments: recruitment rates, data quality, cycle times and inspection outcomes.
Digital vendor assessment: API readiness, AI transparency, cybersecurity assurance and validated integration.
Regulatory readiness: CTIS capability, China IND expertise and UK combined-review readiness.
Two details matter for BD teams. First, Beroe recommends negotiating on cycle time, quality and risk rather than FTE rates, and separating metrics largely within the vendor's control (query closure, RFI turnaround) from sponsor-driven issues. A vendor that arrives with this separation already documented controls the conversation. Second, Beroe tells buyers to design "an integrated supplier ecosystem" linking CROs, digital platforms, logistics and regulatory experts. A vendor that fits into that ecosystem is harder to remove than one that stands alone.
Applied Clinical Trials adds the human factor: sponsors "consistently cite a breakdown in communication as the primary reason for discontinuing a CRO relationship" (Applied Clinical Trials). In other words, a vendor can hit its KPIs and still lose its seat if the relationship feels opaque.
Consolidation is not the same as one vendor: where mid-size providers keep their seat
It is tempting to read the 20 to 40% figure as a death sentence for mid-size providers. The evidence is more nuanced. A 2026 analysis of CDMO network consolidation argues that fewer partners do not automatically produce "lower costs, faster timelines, or stronger performance", that "there is no evidence-based ideal number of CDMOs for a sponsor", and that supplier count and supply protection must be evaluated separately because several CDMOs can share the same upstream manufacturing sites (Pharma's Almanac). The same piece notes that adding a backup supplier to a lean configuration produced the largest improvement among the individual interventions modeled in one oncology injectable reliability model, though it does not support dual sourcing every product.
For BD, the implication is practical. Sponsors that consolidate still need technology transfer capacity, site qualification flexibility and genuine second sources, and they know that technology transfer, validation and post-approval change management can erode the value of consolidation if it is pushed too far. Your job is to be the obvious answer to "why not just give this to our largest partner?" Our earlier work on CDMO selection criteria shows how sponsors score that decision; this article turns the scorecard into a defense plan.
Concentration risk at the top of the market works in your favor too. The five largest CROs are approaching a majority of global CRO market share (GEP), and sponsors deliberately keep boutique and specialist vendors beside the mega-providers to manage that dependence (IntuitionLabs).
Move 1: Specialize so the seat has a reason to exist
A seat is defensible when removing you would leave a gap that the sponsor's primary partner fills badly. That means specializing in something narrow enough to be measurable: a modality, an assay type, a therapeutic area, a regulatory pathway or a geography.
What to do: pick the one or two segments where you outperform the sponsor's largest partner, not merely match it. Document the evidence as numbers: first-pass success rate, turnaround time on that assay, deviations per batch, inspection outcomes. Then write the one-page "why we are the specialist seat" statement and give it to both the category manager and the scientific sponsor.
Why it works: Beroe's finding that large CROs are acquiring niche specialists shows that specialization has real market value. If you do not make your niche visible, a larger provider will eventually buy or imitate it.
Where it fails: specializing in a niche that is too small to matter to procurement, or describing it in capability language instead of outcomes. Our piece on business development challenges for small and mid-sized CROs covers the positioning trap in more detail.
Move 2: Partner so you fit inside the supplier ecosystem
Beroe calls the integrated supplier ecosystem "priority one" for procurement. A mid-size CRO or CDMO that cannot match a mega-provider on breadth can still match it on coverage by partnering with complementary vendors (a digital platform, a logistics provider, a regulatory consultancy, a second-site manufacturer).
What to do: identify two or three partners whose capabilities complete yours and agree on joint offers that sponsors can contract through a single point of contact. Agree on shared governance, escalation paths and data exchange before any pitch. Where the partnership involves data, confirm API readiness and validated integration, which Beroe lists as explicit assessment criteria.
Why it works: it answers the procurement objection that mid-size vendors increase coordination overhead. A pre-built partnership reduces the number of contracts the sponsor manages without reducing the number of specialists it uses.
Where it fails: loose referral arrangements with no shared accountability. Applied Clinical Trials is clear that real partnership means shared governance and mutual accountability, not a logo on a slide.
Move 3: Prove platform value, not project value
Sponsors consolidate toward vendors that can carry more of the program. If your seat is justified only by the last project, it is exposed at the next review. Platform value means showing that your relationship gets better, cheaper or faster with each additional program.
What to do: build a simple account scorecard for every sponsor, using the same KPIs the sponsor's procurement team uses (cycle time, recruitment or batch success, query closure, deviation rate). Share it quarterly, before it is requested. Propose a performance-linked structure for part of the fee, because Beroe expects procurement to move toward linking payments to recruitment, data quality, cycle times and inspection outcomes. Show learning curves: how the second program ran faster than the first.
Why it works: it moves the conversation away from rate cards, which Beroe says buyers should deprioritize relative to productivity, and toward evidence you control.
Where it fails: reporting that is selective or late. A scorecard that hides problems destroys the trust you are trying to build.
Comparison: which defense fits which vendor
Criterion | Specialize | Partner | Prove platform value |
Procurement question it answers | Why not give this to our largest partner? | Does this vendor increase our coordination burden? | Does this relationship get better over time? |
Best fit for | CROs and CDMOs with a clear niche (modality, assay, region) | Providers with a gap in breadth, digital or logistics | Providers with 2 or more active programs at the same sponsor |
Proof sponsors want | Benchmarked results versus a large-provider baseline | A joint offer, a single contract path and shared governance | Quarterly KPI scorecard and learning-curve evidence |
Time to impact | 1 to 2 quarters to document and position | 2 to 4 quarters to build and contract | 1 quarter to start, compounding after |
Main risk | Niche too small or poorly explained | Weak partner accountability | Inconsistent or selective reporting |
Who inside the sponsor to engage | Scientific sponsor first, category manager second | Category manager first | Both, jointly |
Read the table as a selection tool. Most mid-size vendors do best by combining the first and third moves, then adding a partnership only where a real capability gap exists.
A 90-day defense plan for your BD team
Days 1 to 15, map the exposure. List every sponsor account, the date of its next category review if known, the number of vendors in your category and your share of spend. Rank accounts by revenue and by risk of consolidation.
Days 16 to 40, build the evidence. For the top five accounts, assemble the KPI scorecard, the niche statement and any inspection or audit outcomes. Fix data gaps before sharing anything.
Days 41 to 70, run the reviews. Book a structured business review with each top account, with both the scientific sponsor and procurement present where possible. Present the scorecard, ask what the sponsor's consolidation plan is and what would make your seat safer.
Days 71 to 90, formalize. Propose a performance-linked element, a joint governance cadence or a partner offer where relevant. Update your pipeline so that each at-risk account has a named owner and a next action.
Related reading: the broader pipeline discipline behind this plan is covered in our guide to pipeline optimization in life sciences, and the effect of client acquisitions on your contracts in how pharma M&A affects CRO and CDMO contracts.
Early warning signs that you are being consolidated out
Your main contact changes and the new owner is in procurement, not the science team.
You receive an RFI or scorecard request that covers your whole category, not a single project.
Projects move to a larger partner "for continuity" without a competitive process.
Payment terms or rate-card questions start to dominate meetings.
Your sponsor announces an acquisition or a portfolio reprioritization.
Any one of these is a prompt to run the 90-day plan immediately. Waiting for the formal notice usually means the decision has already been made. For the broader context of how a CDMO should handle business development under pressure, and how RFPs should be answered when a re-bid does arrive, see our related guides.
Frequently asked questions
What is CRO vendor consolidation by sponsors? It is the sponsor-side practice of reducing the number of CROs, CDMOs and other service providers it uses, typically by 20 to 40%, and concentrating spend in a few strategic partners per category. It replaces project-by-project bidding with enterprise-wide partnerships governed by shared KPIs.
How can a mid-size CRO or CDMO stay on a sponsor's shortlist? Defend the seat with three moves: specialize in a measurable niche, partner with complementary vendors so you fit the sponsor's supplier ecosystem, and prove platform value with a regular KPI scorecard that shows performance improving across programs. Most mid-size vendors do best combining specialization with platform value.
What do pharma procurement teams measure when they consolidate vendors? According to Beroe, contract and partnership KPIs include enrollment velocity, screen-failure rate, query-closure time, site-activation cycle time, temperature-excursion rates and CTIS RFI turnaround, plus digital readiness and regulatory capability. Buyers are encouraged to prioritize productivity over price cuts.
Does vendor consolidation mean sponsors will use only one CRO or CDMO? No. Analysis of CDMO networks finds there is no evidence-based ideal number of partners, and that consolidation should be treated as network design rather than vendor reduction. Sponsors still need second sources, technology transfer capacity and specialist expertise.
How is staying on a vendor list different from getting on one? Getting on a list is a qualification problem: audits, quality agreements and an MSA. Staying on it is a performance and relationship problem: KPI evidence, account reviews and a clear reason the seat exists. Our guide to the preferred vendor list covers the first; this article covers the second.
Working with Corstrate
Corstrate is a boutique business development consultancy for life sciences service providers: CROs, CDMOs, lab services, regulatory consultancies and clinical technology vendors across the US and EU. We help mid-size providers map their consolidation exposure, build the KPI evidence procurement asks for, and run the account reviews that keep a seat on the shortlist. If you want a fractional BD lead to run this motion, see our fractional business development guide.
Sources
An overview of key procurement trends for clinical development services in 2026, Beroe: https://www.beroeinc.com/resource-centre/insights/clinical-development-services-key-procurement-trends/
The evolution of preclinical CRO strategic partnerships from transactional services, Applied Clinical Trials (September 2026): https://www.appliedclinicaltrialsonline.com/view/evolution-preclinical-cro-strategic-partnerships-transactional-services
How far should CDMO network consolidation go?, Pharma's Almanac: https://www.pharmasalmanac.com/articles/how-far-should-cdmo-network-consolidation-go
Supplier consolidation in the pharmaceutical value chain, GEP: https://www.gep.com/blog/mind/consolidation-suppliers-pharma-value-chain
CRO consolidation and its impact on clinical trials, IntuitionLabs: https://intuitionlabs.ai/articles/cro-consolidation-clinical-trials-impact
All market figures are approximate; research firms differ in methodology and scope.
Imen Jelassi is the Founder of Corstrate, a life sciences business development consultancy working with CROs, CDMOs and pharma service providers in the US and EU.
Comments